2021
DOI: 10.1016/j.jgar.2021.06.015
|View full text |Cite
|
Sign up to set email alerts
|

Standardised treatment protocol for necrotizing otitis externa: retrospective case series and systematic literature review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 18 publications
0
1
0
Order By: Relevance
“…quinolones and Ceftazidime, monotherapy with Ceftazidime, or Piperacillin with Fluoroquinolones. 11 Antimicrobials were changed when indicated by culture (Table 1). Pseudomonas aeruginosa was the usual organism cultured (34%), followed by fungus (21%).…”
Section: Discussionmentioning
confidence: 99%
“…quinolones and Ceftazidime, monotherapy with Ceftazidime, or Piperacillin with Fluoroquinolones. 11 Antimicrobials were changed when indicated by culture (Table 1). Pseudomonas aeruginosa was the usual organism cultured (34%), followed by fungus (21%).…”
Section: Discussionmentioning
confidence: 99%
“…P. aeruginosa is the most common causative pathogen, 5 although infections caused by Staphylococci , Streptococci , and gram-negative bacilli (e.g., Klebsiella , Escherichia ) have also been described. 6 - 8 Recent reports have stressed the occurrence of fungal pathogens that account for 5%-20% with Aspergillus species being the most common. 7 , 36 Six weeks or longer of culture-directed antibiotic therapy is the current standard of treatment.…”
Section: Discussionmentioning
confidence: 99%
“… 2 , 5 A reported incidence of facial nerve (FN) palsy in the course of MEO ranges from 10% to 70%. 1 - 8 The FN paresis may be detected at presentation and may develop despite the treatment. The question arises of how to treat these patients.…”
Section: Introductionmentioning
confidence: 99%
“…As another clinical experience, dual‐antibiotic treatment can be used to treat infections by antibiotic‐resistant bacteria with less chance upon stimulating the development of resistant bacteria. [ 14 ] Here too, nanotechnology offers opportunities to combine currently used antibiotics with new antimicrobials against which bacteria may be unable to develop resistance.…”
Section: Introductionmentioning
confidence: 99%